



भारतीय  
प्रौद्योगिकी  
संस्थान  
काशी हिन्दू विश्वविद्यालय  
INDIAN  
INSTITUTE OF  
TECHNOLOGY  
BANARAS HINDU UNIVERSITY  
DEPARTMENT OF PHARMACEUTICAL ENGINEERING & TECHNOLOGY

**Dr. B. MISHRA,**  
(M. Pharm., Ph.D., FBRs, FSPER)  
Professor of Pharmaceutics

## CERTIFICATE

It is certified that the work contained in the thesis titled *“Development and Evaluation of Lapatinib-Loaded Nanocolloidal Micellar Drug Delivery System for Efficient Treatment of Breast Cancer”* by *“Bonde Gunjan Vasant”* has been carried out under my supervision and that this work has not been submitted elsewhere for a degree.

It is further certified that the student has fulfilled all the requirements of Comprehensive Examination, Candidacy and SOTA for the award of Ph.D. Degree.

**Prof. Brahmeshwar Mishra**  
(Supervisor)

## **DECLARATION BY THE CANDIDATE**

I, "***Bonde Gunjan Vasant***", certify that the work embodied in this thesis is my own bonafide work and carried out by me under the supervision of "***Prof. Brahmeshwar Mishra***" from "***July 2014***" to "***June 2020***", at the "**Department of Pharmaceutical Engineering & Technology**", Indian Institute of Technology (BHU), Varanasi. The matter embodied in this thesis has not been submitted for the award of any other degree/diploma. I declare that I have faithfully acknowledged and given credits to the research workers wherever their works have been cited in my work in this thesis. I further declare that I have not willfully copied any other's work, paragraphs, text, data, results, *etc.*, reported in journals, books, magazines, reports dissertations, theses, *etc.*, or available at websites and have not included them in this thesis and have not cited as my own work.

Date:

Place: Varanasi

***Bonde Gunjan Vasant***

## **CERTIFICATE BY THE SUPERVISOR**

It is certified that the above statement made by the student is correct to the best of my knowledge.

**Prof. Brahmeshwar Mishra**  
(Supervisor)

## **COPYRIGHT TRANSFER CERTIFICATE**

**Title of the Thesis:** *Development and Evaluation of Lapatinib-Loaded Nanocolloidal Micellar Drug Delivery System for Efficient Treatment of Breast Cancer*

**Name of the Student:** *Bonde Gunjan Vasant*

### **Copyright Transfer**

The undersigned hereby assigns to the Indian Institute of Technology (Banaras Hindu University), Varanasi, all rights under copyright that may exist in and for the above thesis submitted for the award of the "*Doctor of Philosophy.*"

**Date:**

*Bonde Gunjan Vasant*

**Place:** Varanasi

**Note:** However, the author may reproduce or authorize others to reproduce material extracted verbatim from the thesis or derivative of the thesis for author's personal use provided that the source and the Institute's copyright notice are indicated.

*Dedicated to my beloved & respected*  
**GURUs, PARENTs AND FRIENDS**

---

## Acknowledgements

---

Foremost, I would like to pay my tribute to the founder of the Banaras Hindu University, Bharat Ratna **Mahamana Pandit Madan Mohan Malaviyaji** whose thoughts and values encourage students to give their best and contribute to the nation building. I am very thankful and proud of the education I received at the Banaras Hindu University.

It is my deep heartfelt interest to express my regards to my supervisor, **Prof. Brahmeshwar Mishra**, who believed me, and gave the opportunity to carry out the research under his guidance. His guidance helped me during the time of research and writing of this thesis. Without his supervision and constant help this dissertation would not have been possible.

I am also grateful to **Prof. Sushant Kumar Shrivastava**, Head, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University) for allowing me to use the Departmental facilities for carrying out my research work.

I owe my gratitude to all my respected RPEC members Dr. Ruchi Chawla and Dr. Abha Mishra (Department of Biochemical Engineering) for their encouragement and insightful comments leading me to the completion of the research work.

I would also like to thank my teachers Prof. S. K. Singh, Prof. Sanjay Singh, Prof. S. Hemalatha, Prof. K. Sairam, Dr. A. K. Srivastava, Dr. S. Raja A., Dr. A. N. Sahu, Dr. Ruchi Chawla, Dr. Ashok Maurya, Dr. M. S. Muthu, Dr. P. K. Nayak, Dr. S.K. Mishra, Dr. G. P. Modi, Dr. S. K. Jain, Dr. V. Tiwari, Dr. A. K. Agarwal, Dr. Rajnish, and Dr. Deepak Kumar.

I take the opportunity to sincerely acknowledge the Ministry of Human Resource Development, Government of India, New Delhi, for providing financial support in the form of Research Fellowship that immensely helped me to achieve my goals.

I would particularly like to acknowledge the contribution of my seniors Dr. Nagendra, Dr. Sandeep, Dr. Sarita, Dr. Gayasuddin Khan, Dr. Ravi, Dr. Pooja Mittal, Dr. Anupam, Dr. Sanjay, Dr. Vijay, Dr. Ramoji Kosuru, Dr. Harshwardhan. It is not sufficient to express my

*gratitude with only a few words. They have always been there to motivate me during the hour of hardship and helped me unconditionally throughout the tenure.*

*I am indeed thankful to have got welcoming and friendly fellow mates Dr. Gufran, Dr. Mansi, Mr. Sathish, Mr. Sandeep, Ms. Kanchan, Ms. Juhi, Ms. Khushboo, Mr. Nitin, Mr. Pawan, Mr. Rajendra, Mr. Madhu Kiran, Mr. Manjit and Mr. Mangal who were ever ready to provide me with all possible help and they created a happy working environment and foster camaraderie within the laboratory.*

*I pay my sincere thanks to Mr. Virendra, Mr. Nandlal, Mr. Chotelal, Mr. Yashwant, Mr. Madan, Mr. Upadhyay, Mr. Jameel, Mr. Pathak, Mr. Rafeeq, Mr. Kapil, Mr. Arun, Mrs. Saroj Kumari, Mrs. Archana Singh, Mr. Atul, Mr. Anand and all other non-teaching staff of the Department for their assistance and co-operation during the Ph.D. tenure.*

*My heartfelt thanks to all my teachers right from school until now for their keen interest, constant encouragement, and wishes for my career. I would also like to thank all of them whoever directly or indirectly helped me complete the research work.*

*I owe my deepest gratitude to my Parents for being a constant source of encouragement and support throughout my life. Their silent sacrifice, moral support, and encouragement cannot be defined in words. It is their love and trust on my abilities which has made me a person I am today. They backed my decision in all peaks and troughs of my life and made it a smooth journey for me.*

*Finally, I thank all those who have helped me directly or indirectly in the successful completion of my thesis. Anyone missed in this acknowledgement are also thanked. I also pray **Lord of Universe** for the animals which were mortified for the cause of research and advancement of knowledge. I wish for their soul to rest in peace.*

**Date:**

**Place:**

*(Bonde Gunjan Vasant)*

---

## TABLE OF CONTENTS

1	Introduction.....	1
2	Literature Review.....	8
2.1	Breast cancer.....	8
2.2	Drug and Excipients profile.....	12
2.2.1	Lapatinib.....	12
2.2.2	Solulpus® .....	14
2.2.3	Kolliphor™ HS 15.....	15
2.2.4	Kolliphor® 407.....	16
2.3	Nanocarrier drug delivery systems .....	17
2.3.1	Nanocolloidal Micelles as DDS.....	19
2.3.2	Polymeric Micelles: .....	22
2.3.3	Mixed / Binary Micelles.....	25
3	Research Envisage and Plan of Work .....	28
3.1	Aim.....	28
3.2	Objective.....	28
3.3	The rationale of a study: .....	28
3.4	Plan of work.....	29
3.4.1	Preformulation studies.....	29
3.4.2	Formulation development and optimization.....	29

---

3.4.3	Physicochemical characterization.....	29
3.4.4	<i>In-Vitro</i> evaluations .....	30
3.4.5	<i>In-vivo</i> evaluations.....	30
<b>4</b>	<b>Material and Methods.....</b>	<b>31</b>
4.1	Materials, Equipment, Software used .....	31
4.1.1	Materials.....	31
4.1.2	Equipments.....	31
4.1.3	Software .....	32
4.2	Pre-formulation studies .....	32
4.2.1	HPLC analytical method development .....	32
4.2.2	Determination of critical micelle concentration (CMC).....	33
4.2.3	Physicochemical characterization of LP and excipients.....	34
4.3	Formulation Development and optimization.....	34
4.3.1	Screening of components for the formulation of micelles.....	34
4.3.2	Optimization of micelles by Box-Behnken Design .....	35
4.3.3	Formulation of micelles .....	35
4.3.4	Physicochemical characterization.....	37
4.3.5	<i>In-vitro</i> Evaluations .....	39
4.3.6	Stability Studies .....	41
4.3.7	Screening of anticancer efficacy.....	42
4.3.8	<i>In-vivo</i> evaluations.....	43

---

4.4 Statistical Analysis .....	45
<b>5 Results and Discussions.....</b>	<b>46</b>
5.1 Pre-formulation Studies.....	46
5.1.1 HPLC analytical method development .....	46
5.1.2 Determination of critical micelle concentration (CMC) .....	48
5.1.3 Physicochemical characterization of LP and excipients .....	51
5.2 Development, optimization and evaluation of Lapatinib-loaded Polymeric Micelles (LP-PMs).....	53
5.2.1 Screening of components for the formulation of micelles .....	53
5.2.2 Optimization of micelles by Box-Behnken Design (BBD).....	58
5.2.3 Formulation of micelles.....	63
5.2.4 Physicochemical characterization of optimized LP-PMs.....	63
5.2.5 <i>In-vitro</i> Evaluations.....	71
5.2.6 Stability Studies .....	76
5.2.7 <i>In-vitro</i> screening of anticancer efficacy.....	78
5.2.8 <i>In-vivo</i> evaluations .....	82
5.3 Development and evaluation of Lapatinib-loaded Binary Micelles (LP-BMs)...	89
5.3.1 Formulation of LP-BMs .....	89
5.3.2 Physicochemical characterization .....	90
5.3.3 <i>In-vitro</i> Evaluations.....	94
5.3.4 Stability Studies .....	97

---

---

5.3.5	<i>In-vitro</i> screening of anticancer efficacy.....	100
5.3.6	<i>In-vivo</i> evaluations.....	102
<b>6</b>	<b>Summary and Conclusions</b> .....	<b>109</b>
6.1	Summary .....	109
6.2	Conclusions .....	113
	<b>References</b> .....	<b>114</b>
	<b>List of Publications</b> .....	<b>126</b>

---

## LIST OF TABLES

<b>Table 2.1</b>	Characteristics of nanocarrier systems and purpose to use for drug delivery	18
<b>Table 5.1</b>	HPLC validation parameters for the determination of lapatinib.....	47
<b>Table 5.2</b>	Inter and Intraday accuracy and precision for HPLC analytical method validation .....	47
<b>Table 5.3</b>	Quality Target Product Profile.....	53
<b>Table 5.4</b>	Control Impact Matrix.....	54
<b>Table 5.5</b>	Critical process parameters and material attributes .....	54
<b>Table 5.6</b>	Risk Estimation Matrix .....	55
<b>Table 5.7</b>	Details of factors used for Plackett-Burman design.....	56
<b>Table 5.8</b>	Composition of LP-PMs as per BBD design.....	58
<b>Table 5.9</b>	Statistical ANOVA results of quadratic model.....	60
<b>Table 5.10</b>	Predicted and experimental values for optimized LP-PMs .....	60
<b>Table 5.11</b>	Results of evaluations for stability studies .....	76
<b>Table 5.12</b>	Estimated pharmacokinetic parameters of different dosage forms.....	83
<b>Table 5.13</b>	Composition of LP-BMs and the results of evaluations.....	89
<b>Table 5.14</b>	Results of evaluations before and after stability studies. ....	98
<b>Table 5.15</b>	Estimated pharmacokinetic parameters of different dosage forms.....	103

---

## LIST OF FIGURES

Figure 2.1 Histological classification of breast cancer.....	10
Figure 2.2 (a) Molecular classification of breast cancer (b) BC subtypes originating from a single mammary stem cell or progenitor cell after activation by different oncogenes; (c) BC heterogeneity initiate from different mammary stem cells or progenitor cells at distinct levels of stem cells proliferation hierarchy.....	11
Figure 2.3 Chemical structure of drug and excipients .....	14
Figure 2.4 Schematic diagrams depicting different nanocarrier drug delivery systems used for delivery of Lapatinib .....	19
Figure 5.1 Calibration curve of Lapatinib in methanol .....	46
Figure 5.2 Calibration curve of Lapatinib in plasma .....	46
Figure 5.3 Graphs showing CMC determination.....	51
Figure 5.4 Pareto charts showing the influence of process variables .....	57
Figure 5.5 3-D response-surface plots .....	61
Figure 5.6 Morphological characterization of LP-PMs: Histograms (A and B) and zeta potential (C and D) .....	64
Figure 5.7 Morphological characterization of LP-PMs: High resolution-scanning electron microscopic images (A and B) of LP-PMs and lyophilized LP-PMs, respectively; Scanning probe microscopic images (C and E) and their histograms (D and F) of LP-PMs and lyophilized LP-PMs, respectively.....	66
Figure 5.8 (A) FT-IR spectra and (B) XRPD diffractograms of pharmaceutical excipients, LP-PMs (C) EDX spectra of LP-PMs .....	68
Figure 5.9 In-vitro drug release profile of (A) LP-PMs micellar dispersion and (B) lyophilized LP-PMs in release media of pH 5.0 and pH 7.4.....	72

---

Figure 5.10 Hemocompatibility studies .....	75
Figure 5.11 Shelf life plots of LP-PMs .....	77
Figure 5.12 <i>In-vitro</i> anti-cancer efficacy studies of LP-PMs against SKBr3 cell line ..	81
Figure 5.13 Comparative plasma drug concentration profiles .....	82
Figure 5.14 <i>In-vivo</i> anticancer efficacy of LP-PMs .....	85
Figure 5.15 The microscopic images of liver sections after staining with H & E stains .....	86
Figure 5.16 (A) Histogram showing the hydrodynamic diameter and (B) zeta potential of LP-BMs; (C and D) High resolution- scanning electron microscopic image showing spherical shape of LP-BMs and lyophilized LP-BMs, respectively. ....	91
Figure 5.17 (A and B) scanning probe microscopic images showing 2-D and 3-D morphology, respectively; (C) FT-IR spectra of LP-BMs and pharmaceutical excipients .....	92
Figure 5.18 (A) EDX spectra of LP-BMs; (B) In-vitro drug release profile of LP- BMs in release media of pH 5.0 and pH 7.4 .....	94
Figure 5.19 (A) Hemocompatibility of LP-BMs in terms of percent hemolysis; (B) platelet aggregation study .....	96
Figure 5.20 Shelf life plots of LP-BMs.....	99
Figure 5.21 <i>In-vitro</i> anti-cancer efficacy studies of LP-PMs against SKBr3 cell line	101
Figure 5.22 Comparative plasma drug concentration profiles .....	104
Figure 5.23 <i>In-vivo</i> anticancer efficacy of LP-BMs. ....	106
Figure 5.24 The microscopic images of liver sections after staining with H & E stains. ....	107

---